Vela purchased Great Basin for $1.4 million in June, and will reopen its Utah-based lab, rehire employees, and commercialize the firm's infectious disease platform.
Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.
True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.
True Health will pay $37.1 million to acquire substantially all the assets of Health Diagnostic Laboratory, which is currently in Chapter 11 reorganization.
A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.
Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.